MX2016004286A - Biomarcadores de cancer y usos de los mismos. - Google Patents
Biomarcadores de cancer y usos de los mismos.Info
- Publication number
- MX2016004286A MX2016004286A MX2016004286A MX2016004286A MX2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- specific binding
- binding member
- domain
- cancer biomarkers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317622.7A GB201317622D0 (en) | 2013-10-04 | 2013-10-04 | Cancer biomarkers and uses thereof |
| PCT/GB2014/052994 WO2015049537A1 (en) | 2013-10-04 | 2014-10-03 | Cancer biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004286A true MX2016004286A (es) | 2017-01-18 |
Family
ID=49630223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004286A MX2016004286A (es) | 2013-10-04 | 2014-10-03 | Biomarcadores de cancer y usos de los mismos. |
Country Status (20)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| PL3241842T3 (pl) | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016162505A1 (en) * | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019122882A1 (en) * | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| CN112584862A (zh) * | 2018-05-17 | 2021-03-30 | 伊米若梅有限公司 | Ch3结构域表位标签 |
| CN108875302B (zh) * | 2018-06-22 | 2022-02-22 | 广州漫瑞生物信息技术有限公司 | 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| KR102325731B1 (ko) * | 2020-01-15 | 2021-11-15 | 주식회사 베르티스 | 암의 진단용 조성물 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) * | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| PL3241842T3 (pl) * | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US20120121586A1 (en) * | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
-
2013
- 2013-10-04 GB GBGB1317622.7A patent/GB201317622D0/en not_active Ceased
-
2014
- 2014-10-03 AU AU2014330942A patent/AU2014330942A1/en not_active Abandoned
- 2014-10-03 PE PE2016000450A patent/PE20160950A1/es not_active Application Discontinuation
- 2014-10-03 ES ES14781645.8T patent/ES2687783T3/es active Active
- 2014-10-03 CN CN201480055024.5A patent/CN105722997A/zh active Pending
- 2014-10-03 JP JP2016546183A patent/JP6449308B2/ja not_active Expired - Fee Related
- 2014-10-03 DK DK14781645.8T patent/DK3052647T3/en active
- 2014-10-03 WO PCT/GB2014/052994 patent/WO2015049537A1/en not_active Ceased
- 2014-10-03 LT LTEP14781645.8T patent/LT3052647T/lt unknown
- 2014-10-03 EA EA201690450A patent/EA201690450A1/ru unknown
- 2014-10-03 SG SG11201602605TA patent/SG11201602605TA/en unknown
- 2014-10-03 EP EP14781645.8A patent/EP3052647B1/en active Active
- 2014-10-03 CA CA2925186A patent/CA2925186A1/en not_active Abandoned
- 2014-10-03 BR BR112016007348A patent/BR112016007348A2/pt not_active Application Discontinuation
- 2014-10-03 MX MX2016004286A patent/MX2016004286A/es unknown
- 2014-10-03 KR KR1020167011055A patent/KR20160092992A/ko not_active Withdrawn
- 2014-10-03 HR HRP20181566TT patent/HRP20181566T1/hr unknown
-
2016
- 2016-03-08 IL IL244510A patent/IL244510A0/en unknown
- 2016-03-31 US US15/087,272 patent/US20160289336A1/en not_active Abandoned
- 2016-04-04 CL CL2016000777A patent/CL2016000777A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105722997A (zh) | 2016-06-29 |
| PE20160950A1 (es) | 2016-10-02 |
| CA2925186A1 (en) | 2015-04-09 |
| HK1221746A1 (en) | 2017-06-09 |
| AU2014330942A1 (en) | 2016-05-19 |
| KR20160092992A (ko) | 2016-08-05 |
| SG11201602605TA (en) | 2016-04-28 |
| HRP20181566T1 (hr) | 2018-11-30 |
| CL2016000777A1 (es) | 2017-02-17 |
| GB201317622D0 (en) | 2013-11-20 |
| JP6449308B2 (ja) | 2019-01-09 |
| ES2687783T3 (es) | 2018-10-29 |
| US20160289336A1 (en) | 2016-10-06 |
| BR112016007348A2 (pt) | 2018-01-23 |
| LT3052647T (lt) | 2018-10-25 |
| DK3052647T3 (en) | 2018-10-22 |
| EP3052647B1 (en) | 2018-07-11 |
| IL244510A0 (en) | 2016-04-21 |
| EP3052647A1 (en) | 2016-08-10 |
| WO2015049537A1 (en) | 2015-04-09 |
| EA201690450A1 (ru) | 2016-10-31 |
| JP2016533395A (ja) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690450A1 (ru) | Биомаркеры рака и их применения | |
| MX2016007885A (es) | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. | |
| NZ603271A (en) | Anti-erbb3 antibodies | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| MY192474A (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG10201908558WA (en) | Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| AU2015347015A8 (en) | Antibody drug conjugates | |
| MX2019003942A (es) | Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cancer. | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| DK2766040T3 (da) | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie | |
| NZ611785A (en) | Anti-notch1 antibodies | |
| MX2011010955A (es) | Terapia complementaria contra el cancer. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| PH12016500580A1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
| IN2014DN09717A (cg-RX-API-DMAC10.html) | ||
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |